Navigation Links
Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
Date:9/14/2007

consisted of $5.1 million of royalty fees earned from the commercial sales of memantine by Merz and its marketing partners in the United States and certain European countries, $3.2 million from the sale of NTI's rights and assets related to XERECEPT to Celtic, and $4.0 million from the reimbursement of the direct expenses incurred for the services provided to Celtic.

Research and development expenses of $26.7 million in the year ended June 30, 2007 increased by $3.9 million compared to R&D expenses of $22.8 million in fiscal year 2006. During fiscal year 2007, $21.2 million of the R&D expenses were focused on Viprinex(TM), with the remaining $5.5 million on XERECEPT. The increase in research and development expenses resulted from an additional $5.2 million of expenses incurred for the Phase 3 clinical trials of Viprinex, which was partially offset by a decrease of $1.3 million of reimbursed expenses for the continuing Phase 3 clinical trials for XERECEPT.

The Company had no acquired in-process research and development expenses for the fiscal year ended June 30, 2007 compared to $11.5 million for the fiscal year ended June 30, 2006. The 2006 expenses represented the expensing of certain tangible and intangible assets related to the acquisition of Empire Pharmaceuticals from 2005.

General and administrative expenses totaled $6.5 million for the year ended June 30, 2007 compared to $6.0 million in fiscal year 2006. The increase in general and administrative expenses resulted primarily from increases of approximately $362,000 for compensation, $259,000 for consultants and $276,000 for audit fees, offset by a $243,000 decrease in legal fees.

Investment income for the fiscal year ended June 30, 2007 totaled approximately $494,000 compared to $399,000 in fiscal year 2006. The increase was due to higher average cash balances in fiscal 2007 and an increase in our average rate of return on our investment portfolio.

Gain on change in value of warr
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... PHILADELPHIA , Nov. 26, 2014 /PRNewswire-USNewswire/ ... unforgiving environments. Human exploration of space requires astronauts to ... mission safety and success, and prevent potential errors and ... success, little is known about how cognition is affected ... primarily affected. Now, Penn Medicine researchers are ...
(Date:11/26/2014)... On January, 14, 2015, UMBC’s Biotechnology ... science community to the UMBC campus for a discussion ... Protein Society, will take place from 9 a.m. to ... Through discussion, presentations and workshops, the free symposium will ... role in the industry and the future of protein ...
(Date:11/26/2014)... PMG Research, Inc. announced today the formation ... of sites that provide clinical research services to pharmaceutical companies ... through its partnerships with large physician practices and integrated health ... in the Southeastern United States and spans over 60 physician ... will be held by: Dr. Robert Holmes, MD, of ...
(Date:11/26/2014)... NC (PRWEB) November 25, 2014 ... Intensity Focused Ultrasound (HIFU) devices, recently participated in ... Small Renal Mass 360° .” Key opinion leaders ... therapeutic advances related to small renal masses while ... about different ablative technologies in hands-on labs. Attendees ...
Breaking Biology Technology:Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 2Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 4PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3
... Nov. 15 China Aoxing Pharmaceutical,Company, Inc. (OTC ... and product pipeline for highly regulated narcotic,medicines and ... the first quarter of fiscal 2008 ended September ... revenues of $1,380,294 for,the first quarter of fiscal ...
... Final Close Completes $35 Million Financing, WOBURN, Mass., ... new generation biologics for the treatment and,prevention of cancer ... E financing, concurrent with the completion of a,venture debt ... BioVex intends to use the capital to complete its ...
... NASA Goddard Space Flight Center in Greenbelt, Md. ... nanotubes (CNT) has been named a winner in the ... Technology category. This award will be celebrated at the ... Tech Briefs National Nano Engineering Conference (NNEC 2007) in ...
Cached Biology Technology:China Aoxing Pharmaceutical Reports Financial Results for the First Quarter of Fiscal 2008 2China Aoxing Pharmaceutical Reports Financial Results for the First Quarter of Fiscal 2008 3China Aoxing Pharmaceutical Reports Financial Results for the First Quarter of Fiscal 2008 4China Aoxing Pharmaceutical Reports Financial Results for the First Quarter of Fiscal 2008 5BioVex Closes Second Round of Series E Financing 2NASA Goddard Space Flight Center's carbon nanotube manufacturing technology wins Nano 50 Award 2
(Date:11/5/2014)... biology in the UTSA College of Sciences, is ... to receive a two-year $300,00 National Science Foundation ... The funding supports President Obama,s BRAIN Initiative, a ... technology that will demystify complex brain processes. ... are broken into the interactions of multiple components, ...
(Date:11/4/2014)... of Utah engineers developed the first room-temperature fuel cell ... without needing to ignite the fuel. These new fuel ... power and sensors. , A study of the new ... journal ACS Catalysis . , Fuel cells convert ... fuel and an oxygen-rich source such as air. If ...
(Date:11/4/2014)... — Think about the way our bodies are assembled ... know that they are supposed to become a nerve ... find the correct place and alignment? Researchers at the ... , In a new study, UM researchers describe the ... surrounding neighbors, at the head-trunk region. Their discovery may ...
Breaking Biology News(10 mins):UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3Jet-fueled electricity at room temperature 2The inside story: How the brain and skull stay together 2
... And if one wants to make something work using ... behavior of cells is a good place to start ... a very tiny packet. As Erik Winfree, professor of ... "I tend to think of cells as really small ...
... Rett Syndrome Foundation (IRSF) announces today ten (10) new ... Translational Research Program; and additional funding for current human ... 2013 covers the spectrum of Rett syndrome research, from ... way to treating the girls diagnosed with Rett syndrome. ...
... more than a trillion cells called neurons that form a ... contains millions of proteins that perform different functions. Exactly how ... brain still remains as a mystery that is just beginning ... of scientists has been able to observe intact interactions between ...
Cached Biology News:Building artificial cells will be a noisy business 2Building artificial cells will be a noisy business 3IRSF announces 2013 awards and implements new Translational Program 2IRSF announces 2013 awards and implements new Translational Program 3Watching how the brain works 2
Immunogen: Extract of pigmented melanoma metastases from lymph nodes. Storage: -20 C, Avoid Freeze/Thaw Cycles...
with GlutaMAXIL-glutamine...
alpha N-catenin (C-19)...
This STAT antibody sampler pack contains 8 monoclonal ,STAT antibodies....
Biology Products: